These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 25764941)

  • 1. Identification of a candidate therapeutic antibody for treatment of canine B-cell lymphoma.
    Rue SM; Eckelman BP; Efe JA; Bloink K; Deveraux QL; Lowery D; Nasoff M
    Vet Immunol Immunopathol; 2015 Apr; 164(3-4):148-59. PubMed ID: 25764941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and biologic activity of a canine anti-CD20 monoclonal antibody in dogs with diffuse large B-cell lymphoma.
    McLinden GP; Avery AC; Gardner HL; Hughes K; Rodday AM; Liang K; London CA
    J Vet Intern Med; 2024; 38(3):1666-1674. PubMed ID: 38662527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of rituximab in the treatment of canine lymphoma: an ex vivo evaluation.
    Impellizeri JA; Howell K; McKeever KP; Crow SE
    Vet J; 2006 May; 171(3):556-8. PubMed ID: 16624725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel anti-CD20 antibody TGLA with enhanced antibody-dependent cell-mediated cytotoxicity mediates potent anti-lymphoma activity.
    Lv M; Lin Z; Qiao C; Gen S; Lang X; Li Y; Feng J; Shen B
    Cancer Lett; 2010 Aug; 294(1):66-73. PubMed ID: 20202740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of a canine anti-canine CD20 antibody for canine lymphoma treatment.
    Mizuno T; Kato Y; Kaneko MK; Sakai Y; Shiga T; Kato M; Tsukui T; Takemoto H; Tokimasa A; Baba K; Nemoto Y; Sakai O; Igase M
    Sci Rep; 2020 Jul; 10(1):11476. PubMed ID: 32651429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.
    Betting DJ; Yamada RE; Kafi K; Said J; van Rooijen N; Timmerman JM
    J Immunother; 2009; 32(6):622-31. PubMed ID: 19483647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20.
    Maddipatla S; Hernandez-Ilizaliturri FJ; Knight J; Czuczman MS
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4556-64. PubMed ID: 17671142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.
    Borgerding A; Hasenkamp J; Engelke M; Burkhart N; Trümper L; Wienands J; Glass B
    Exp Hematol; 2010 Mar; 38(3):213-21. PubMed ID: 20056126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines.
    Flieger D; Renoth S; Beier I; Sauerbruch T; Schmidt-Wolf I
    Cell Immunol; 2000 Aug; 204(1):55-63. PubMed ID: 11006018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eradication of Canine Diffuse Large B-Cell Lymphoma in a Murine Xenograft Model with CD47 Blockade and Anti-CD20.
    Weiskopf K; Anderson KL; Ito D; Schnorr PJ; Tomiyasu H; Ring AM; Bloink K; Efe J; Rue S; Lowery D; Barkal A; Prohaska S; McKenna KM; Cornax I; O'Brien TD; O'Sullivan MG; Weissman IL; Modiano JF
    Cancer Immunol Res; 2016 Dec; 4(12):1072-1087. PubMed ID: 27856424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD20 expression in normal canine B cells and in canine non-Hodgkin lymphoma.
    Jubala CM; Wojcieszyn JW; Valli VE; Getzy DM; Fosmire SP; Coffey D; Bellgrau D; Modiano JF
    Vet Pathol; 2005 Jul; 42(4):468-76. PubMed ID: 16006606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a monoclonal antibody for the detection of anti-canine CD20 chimeric antigen receptor expression on canine CD20 chimeric antigen receptor-transduced T cells.
    Sakai O; Ogino S; Tsukui T; Igase M; Mizuno T
    J Vet Med Sci; 2021 Oct; 83(10):1495-1499. PubMed ID: 34408098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Canine CD20 gene.
    Kano R; Inoiue C; Okano H; Yamazaki J; Takahashi T; Watari T; Tokuriki M; Hasegawa A
    Vet Immunol Immunopathol; 2005 Dec; 108(3-4):265-8. PubMed ID: 16061290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Rituximab, a chimeric mouse-human anti-CD20 monoclonal antibody].
    Tobinai K
    Nihon Rinsho; 2002 Mar; 60(3):468-72. PubMed ID: 11904960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Rituximab, a chimeric anti-CD20 monoclonal antibody, in the treatment of B-cell lymphoma].
    Tobinai K
    Gan To Kagaku Ryoho; 2002 Mar; 29(3):473-80. PubMed ID: 11915743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of a humanized anti-CD20 antibody with potent antitumor activity against B-cell lymphoma.
    Wu L; Wang C; Zhang D; Zhang X; Qian W; Zhao L; Wang H; Li B; Guo Y
    Cancer Lett; 2010 Jun; 292(2):208-14. PubMed ID: 20056316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma.
    Flavell DJ; Warnes SL; Bryson CJ; Field SA; Noss AL; Packham G; Flavell SU
    Br J Haematol; 2006 Jul; 134(2):157-70. PubMed ID: 16771848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An anti-CD20-IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma.
    Gillies SD; Lan Y; Williams S; Carr F; Forman S; Raubitschek A; Lo KM
    Blood; 2005 May; 105(10):3972-8. PubMed ID: 15692062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical study of Ublituximab, a Glycoengineered anti-human CD20 antibody, in murine models of primary cerebral and intraocular B-cell lymphomas.
    Ben Abdelwahed R; Donnou S; Ouakrim H; Crozet L; Cosette J; Jacquet A; Tourais I; Fournès B; Gillard Bocquet M; Miloudi A; Touitou V; Daussy C; Naud MC; Fridman WH; Sautès-Fridman C; Urbain R; Fisson S
    Invest Ophthalmol Vis Sci; 2013 May; 54(5):3657-65. PubMed ID: 23611989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
    Gellrich S; Muche JM; Wilks A; Jasch KC; Voit C; Fischer T; Audring H; Sterry W
    Br J Dermatol; 2005 Jul; 153(1):167-73. PubMed ID: 16029344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.